GRT-R902

Seattle Project Corporation · Phase 2 active Small molecule

At a glance

Generic name	GRT-R902
Sponsor	Seattle Project Corporation
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer (PHASE2, PHASE3)
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer (PHASE2)
A Study of a Personalized Neoantigen Cancer Vaccine (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GRT-R902 CI brief — competitive landscape report
GRT-R902 updates RSS · CI watch RSS
Seattle Project Corporation portfolio CI